Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.52 |
| ▸ | LIPG | Q9Y5X9 | 8/20 | 0.51 |
| ▸ | LPL | P06858 | 7/20 | 0.51 |
| ▸ | F11 | P03951 | 3/20 | 0.50 |
| ▸ | F2 | P00734 | 2/20 | 0.50 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.50 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.50 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.50 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.46 |
| ▸ | P4HB | P07237 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 4/20 | 0.43 |
| ▸ | CA2 | P00918 | 4/20 | 0.43 |
| ▸ | CA9 | Q16790 | 4/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA3 | P07451 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA6 | P23280 | 1/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28980531 | 0.85 | LIPG (0.56) | ESR2LIPGLPLF11F2 | |
| SCHEMBL16501553 | 0.84 | ESR2 (0.49) | ESR2LIPGLPLF11F2 | |
| SCHEMBL12675946 | 0.84 | SLC7A5 (0.53) | ESR2LIPGLPLF11F2 | |
| SCHEMBL14672691 | 0.81 | ESR2 (0.49) | ESR2LIPGLPLF11F2 | |
| SCHEMBL4472450 | 0.81 | ESR2 (0.49) | ESR2LIPGLPLF11F2 | |
| SCHEMBL648399 | 0.80 | LIPG (0.61) | ESR2LIPGLPLF11F2 | |
| SCHEMBL5761714 | 0.79 | PPARA (0.54) | ESR2LIPGLPLF11F2 | |
| SCHEMBL17939953 | 0.79 | P4HB (0.40) | ESR2LIPGLPLF11F2 | |
| SCHEMBL7903372 | 0.78 | F11 (0.50) | ESR2LIPGLPLF11F2 | |
| SCHEMBL902460 | 0.78 | LIPG (0.69) | ESR2LIPGLPLF11F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110301349-A1 | METHODS OF PREPARING 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS | TERSERA THERAPEUTICS LLC | 2011-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301349-A1 | METHODS OF PREPARING 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS | DPYD, TYMP, NUDT1 | ESR2 2524/4885LIPG 3808/4885LPL 3838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.